Lisa Wojcik

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

Alexandra Trkola, Shawn E. Kuhmann, Julie Strizki et al. · Proceedings of the National Academy of Sciences · 2002 · 304 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +15

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection <i>in vitro</i> and <i>in vivo</i>

Julie Strizki, Serena Xu, Nicole Wagner et al. · Proceedings of the National Academy of Sciences · 2001 · 300 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

Julie Strizki, Cécile Tremblay, Serena Xu et al. · Antimicrobial Agents and Chemotherapy · 2005 · 214 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(<i>S</i>)-methyl-4-[1(<i>S</i>)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine <i>N</i>1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist

Jayaram R. Tagat, Ruo W. Steensma, Stuart W. McCombie et al. · Journal of Medicinal Chemistry · 2001 · 113 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Metal/insulator composite selective absorbers

H. G. Craighead, R. Bartynsky, R. A. Buhrman et al. · Solar Energy Materials · 1979 · 107 citations

Natural Sciences, Materials Engineering, Materials Science +10